Andrius Zucenka

6PUBLICATIONS
40CO-AUTHORS
Gene and molecular therapyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|Jan 31, 2024
Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.

Andrius Zucenka, Laimonas Griskevicius

|Apr 17, 2022
Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies.

Lukas Kevlicius, Ruta Cepulyte, Dominika Vasilevska

|Jul 18, 2021
Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation.

Andrius Zucenka, Vilmante Vaitekenaite, Kazimieras Maneikis

|Oct 30, 2020
Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation.

Rūta Čepulytė, Andrius Žučenka, Valdas Pečeliūnas

|Sep 30, 2020
Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies.

Andrius Zucenka, Regina Pileckyte, Igoris Trociukas

Pageof 1

Frequent Collaborators

1 joint publications

Regina Pileckyte

1 joint publications

Vilmante Vaitekenaite

1 joint publications

Rūta Čepulytė

1 joint publications

Valdas Pečeliūnas